Ionis Pharmaceuticals Inc at BMO Capital Markets Growth & ESG Conference Transcript
Hello, everyone. Thanks for attending today's session. My name is Kostas Biliouris, and I am one of the biotech analysts here at BMO Capital Markets. It's a pleasure to have here with me the CEO of Ionis Pharmaceuticals, Brett Monia. And thank you, Brett. Thanks for joining us today. It's a great pleasure to have you here.
And maybe we can start with a high-level overview of the company, and then -- for those who are not familiar with Ionis, and then we can take it from there with more specific questions. Thank you.
Sounds great, Kostas. Thank you for the invitation to be here today. It's a pleasure to provide an update on the great progress we're making at Ionis.
So Ionis, for those that aren't that familiar with the company, we are a well-established biotech company, now nearly 34 years old. We were created to really pioneer a new way of discovering and delivering
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |